Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Biousian Biosystems Receives US Patent

Published: Tuesday, December 17, 2013
Last Updated: Monday, December 16, 2013
Bookmark and Share
Patent provides composition of matter protection for a series of highly selective delta opioid receptor agonists.

Biousian Biosystems Inc, (BBI) has announced that the U.S. Patent and Trademark Office has issued a patent to BBI (U.S. Patent 8,575,309).

The patent describes a series of highly selective and potent delta opioid receptor agonists for the treatment of acute and chronic pain. One of the molecules covered by the patent is BBI-11008, the company’s lead drug that is positioned as a best-in-class analgesic.

BBI-11008 is an orally available drug that has equivalent efficacy to opioids but exhibits markedly reduced side effects in preclinical models. Due to the unique delta opioid selectivity of BBI-11008, it lacks the toxicities usually associated with mu selective opioid agonists (e.g. morphine), including respiratory distress, GI tract immobility and has no evidence of addiction. The molecule’s performance has been studied in extensive in-vivo preclinical pain studies, funded by multiple NIH SBIR grants.

Ed Bilsky, Founder of Biousian Biosystems and Professor of Biomedical Sciences at the University of New England, said, “Delta opioid receptors were first described in the 1970s, but multiple efforts to develop a highly selective agonist with drug-like properties have failed. Our novel synthetic chemistry applied to naturally occurring enkephalin opioid peptides enable us to impart small-molecule, drug-like properties to peptides. The lead molecule has therapeutic utility across a broad range of pain indications, including neuropathic pain, inflammatory pain, cancer pain and migraine.”

Robin Polt, Founder of Biousian Biosystems and Professor of Chemistry and Biochemistry, and BIO5 at the University of Arizona said, “We are very excited about the prospects for glycopeptide drugs that increase drug stability and increase penetration across the blood-brain barrier and into the central nervous system. Biologically compatible glycosides such as BBI-11008 are metabolized into simple amino acids and sugars that are more properly regarded as nutrients, in contrast to classical opioid alkaloids that produce a cascade of toxic metabolites.”

Mark Philip, acting President of Biousian Biosystems said “We are delighted to have made such rapid progress and achieved proof of principle for both efficacy and safety for BBI-11008 in a range of preclinical models. This, together with the recently-issued patent protection for this series of molecules, encourages us to accelerate the work towards moving the lead candidate into the clinic.”

Biousian is actively exploring both corporate partnerships and/or equity investment to progress this molecule into clinical trials. The company’s business development is being supported by Alacrita Consulting.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukemia
Potential for halting disease in molecule isolated from sea sponges.
Molecular ‘Kiss Of Death’ Flags Pathogens For Destruction
Researchers have discovered that our bodies mark pathogen-containing vacuoles for destruction by using a molecule called ubiquitin, commonly known as the "kiss of death."
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Diagnostics Breakthrough Brings Viral Sequencing to Doctors’ Toolkit
New screening tool produces up to 10,000-fold improvement in viral matches compared with traditional high-throughput methods.
New Virus Identified In Blood Supply
Scientists have discovered a new virus that can be transmitted through the blood supply.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos